Aurigene and Vipergen partner to offer DNA encoded library (DEL) screening and integrated drug discovery service

HYDERABAD, India — Aurigene Pharmaceutical Services Ltd., a global contract research, development, and manufacturing services organization (CRDMO); and Vipergen ApS, a niche small-molecule drug discovery service provider specializing in DNA encoded library (DEL) technologies; have partnered to co-market and offer DEL screening technologies as a standalone service or as an integrated drug discovery service. The two companies will also co-develop new DELs with an emphasis on novel chemical diversity and drug-likeness to further strengthen their offering.

The collaboration aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening more than one billion small-molecule compounds either in a living cell or on a purified drug target protein.

By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, the companies will integrate and enhance their end-to-end discovery solution, by offering expedited hit identification.

Vipergen’s high-fidelity DEL screening technologies would be a strategic addition to Aurigene’s existing small molecule discovery capabilities, from compound resynthesis to candidate nomination. With the addition of hit screening capabilities, Aurigene would be able to enhance its integrated drug discovery (IDD) service offering to global customers.

“The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer-centric approach. The recent launch of Aurigene.AI for small molecules and DEL partnership with Vipergen aim to reduce the hit finding timelines. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us.”, said Akhil Ravi, CEO of Aurigene.

“We are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.”, said Nils Jakob Vest Hansen, CEO of Copenhagen-based Vipergen.

Aurigene, a Dr. Reddy’s Laboratories company, is built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development, and manufacturing of small and large molecules. It offers integrated and standalone services for discovery chemistry, biotherapeutics discovery, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. More details about Aurigene are available at www.aurigeneservices.com.